Geneva, Switzerland (PRWEB) July 30, 2014
Selexis SA, a serial innovation company with proven technologies for biologic drug discovery and mammalian cell line development, announced today new data from the Company’s SURE CHO-Mplus Libraries™ will be presented at the 10th Annual Cell Line Development and Engineering conference being held, September 8 – 10, 2014 at the Double Tree by Hilton Berkeley Marina in Berkeley, California.
The following abstract will be presented during an oral presentation:
Title: Genome Engineering Using Larger or Multiple Inserts
Presenter: Pierre-Alain Girod, PhD, Chief Science Officer
- Session Date/Time: Monday, September 8, 2014 at 9:45 AM
- Session Detail: Progress in Host Cell Engineering tract
Utilizing the data from the completed CHO-M Genome and Transcriptome project, we identified areas in the CHO-M secretory pathway where key secretory pathways proteins levels were either missing or expressed at inappropriate levels. We concurrently developed a vector system that allowed us to engineer the CHO-M secretory pathway by inserting multiple genes into the genome simultaneously. Using this technology, we generated a panel of CHO-based libraries consisting of multiple genes addressing key issues associated with effective translation, translocation and secretion. A case study evaluating co-expression of multiple chaperones simultaneously on recombinant protein production levels will be presented.
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company’s SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.
For more information: